Plus   Neg

Sohu Lifts Q4 Outlook On Strong Performance In Online Game Business

Chinese online media and gaming business Sohu.com Limited (SOHU) announced Friday that it is lifting fourth-quarter outlook.

The revision in outlook is based on better than expected performance of the online game business, a tax benefit of $19 million expected to be recognized for some of Changyou's subsidiaries, and an impairment charge of approximately $23 million for an investment unrelated to the Company's core businesses.

For the fourth quarter of 2019, Sohu now estimates attributable net loss, including the expected impairment charge, between $15 million and $25 million or $0.40 to $0.65 per ADS. The previous outlook was attributable net loss between $17 million and $27 million or $0.45 to $0.70 per ADS.

Excluding the impairment charge, adjusted attributable net income would be between nil and $10 million or nil to $0.25 per ADS. The previous outlook was loss between $12 million and $22 million or $0.30 to $0.55 per ADS.

Excluding the profit generated by Sogou and Changyou, and further excluding the expected impairment charge, adjusted net loss would be between $45 million and $50 million.

The company now projects total revenues between $465 million and $500 million, compared to earlier estimate of $435 million to $470 million.

Online game revenues are now projected to be between $125 million and $135 million, up from previous estimate of $95 million to $105 million.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Novacyt S.A. said it is seeing unprecedented demand for the novel coronavirus or COVID-19 diagnostic test kit developed by Primerdesign, the company's molecular diagnostics division based in the UK. As of March 27, Primerdesign has sold and received orders for more than 17.8 million pounds of its CE-Mark COVID-19 tests. Novacyt is currently selling its COVID-19 test to more than 80 countries. The U.S. Food and Drug Administration has issued an Emergency Use Authorization to allow anti-malaria drugs hydroxychloroquine sulfate and chloroquine phosphate donated to the Strategic National Stockpile as possible treatments for coronavirus (COVID-19) patients. This is the first EUA for a drug related to the COVID-19 response. Gilead Sciences Inc. said it is transitioning to "expanded access programs" from "compassionate use" programs for its experimental anti-coronavirus drug, remdesivir. The company noted that the expanded access will allow hospitals or physicians to apply for emergency use of remdesivir for multiple severely ill patients at one time, as they struggle to deal with the COVID-19 or coronavirus pandemic.
Follow RTT